# Anti-CD33-CLL1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

> **NCT07668557** · PHASE1 · RECRUITING · sponsor: **iCell Gene Therapeutics** · enrollment: 18 (estimated)

## Conditions studied

- Acute Myeloid Leukemia (AML)

## Interventions

- **BIOLOGICAL:** Anti-CD33-CLL1 CAR-T cells (ICG415) following lymphodepleting fludarabine and cyclophosphamide

## Key facts

- **NCT ID:** NCT07668557
- **Lead sponsor:** iCell Gene Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-10
- **Primary completion:** 2028-07-04
- **Final completion:** 2029-07-04
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07668557

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07668557, "Anti-CD33-CLL1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07668557. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*